Griffin Hospital, Derby, CT
Thanathip Suenghataiphorn , Narathorn Kulthamrongsri , Tuntanut Lohawatcharagul , Chalermkiat Kansuttiviwat , Sakditad Saowapa
Background: Literature review has found profound disparities in clinical outcomes, for patient with ovarian cancer. Metastasis is the primary cause of cancer morbidity and mortality. However, data on the metastasis risks on hospitalized individuals with ovarian cancer is still limited. Therefore, we aim to assess the association between metastatic ovarian cancer and racial differences using large database analysis. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to explore patients who have ovarian cancer as the primary diagnosis. Additionally, we identified evidence of metastasis, as recorded by ICD-10-CM. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was racial differences in organ metastasis and secondary outcomes included mortality and length of stay. Statistical significance was established at p-value of 0.05. Results: We identified 19,789 patients with primary diagnosis of ovarian cancer at discharge. The mean age was 61.6 years. Caucasians accounted for 68.3%, with Hispanics at 11.1 % and African Americans at 9.7%. We found that 7% of the patients had liver metastasis. In a multivariate analysis adjusting for patient, COVID-19, chemotherapy usage and hospital factors, African Americans and Hispanics had higher risk of liver metastasis (aOR 1.95; 95%CI (1.32, 2.88), p = 0.001) (aOR 1.78; 95%CI (1.19, 2.66), p = 0.004). We also observed reduced length of stay for Asian Americans (b = -0.74; 95%CI (-1.31, -0.17), p = 0.011). We observed an increase in risk of metastasis and mortality but non-statistically significant in some parameters and races, as shown in table provided. Conclusions: In conclusion, our study revealed that racial difference is associated with higher risk of metastasis, as well as other outcomes. More studies following patients over time are needed to determine if race directly affects how ovarian cancer spreads and other clinical outcomes.
Race | Liver Metastasis | Lung Metastasis | Mortality | Length of Stay** |
---|---|---|---|---|
Caucasian | Baseline | |||
African American | 1.95 (1.32, 2.88)* | 1.11 (0.83, 1.43) | 1.73 (0.86, 3.49) | 0.49 (-0.20, 1.20) |
Hispanic | 1.78 (1.19, 2.66)* | 1.15 (0.86, 1.48) | 0.52 (0.19, 1.43) | -0.20 (-0.77, 0.37) |
Asian | 1.05 (0.59, 1.89) | 0.86 (0.57, 1.29) | 0.72 (0.22, 2.28) | -0.74 (-1.31, -0.17)* |
Native American | 0.60 (0.08, 4.36) | 0.55 (0.22, 1.36) | N/A | -0.51 (-2.18, 1.15) |
Others | 1.48 (0.69, 3.16) | 1.48 (0.84, 2.62) | 0.88 (0.31, 2.46) | 0.45 (-1.12, 2.02) |
*Denotes statistically significant at p-level < 0.05.
**Length of Stay is expressed as beta-coefficient.
N/A denotes no death in the subpopulation group.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Mrunanjali Gaddam
2024 ASCO Annual Meeting
First Author: Edward Christopher Christopher Dee
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Jeffrey Lee
2022 ASCO Annual Meeting
First Author: Meri Tarockoff